1. Home
  2. RIGL vs EFT Comparison

RIGL vs EFT Comparison

Compare RIGL & EFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • EFT
  • Stock Information
  • Founded
  • RIGL 1996
  • EFT 2004
  • Country
  • RIGL United States
  • EFT United States
  • Employees
  • RIGL N/A
  • EFT N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • EFT Finance Companies
  • Sector
  • RIGL Health Care
  • EFT Finance
  • Exchange
  • RIGL Nasdaq
  • EFT Nasdaq
  • Market Cap
  • RIGL 335.5M
  • EFT 327.7M
  • IPO Year
  • RIGL 2000
  • EFT N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • EFT $12.08
  • Analyst Decision
  • RIGL Buy
  • EFT
  • Analyst Count
  • RIGL 5
  • EFT 0
  • Target Price
  • RIGL $38.20
  • EFT N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • EFT 100.8K
  • Earning Date
  • RIGL 08-05-2025
  • EFT 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • EFT 10.63%
  • EPS Growth
  • RIGL N/A
  • EFT N/A
  • EPS
  • RIGL 5.43
  • EFT 1.73
  • Revenue
  • RIGL $267,921,000.00
  • EFT N/A
  • Revenue This Year
  • RIGL $59.93
  • EFT N/A
  • Revenue Next Year
  • RIGL N/A
  • EFT N/A
  • P/E Ratio
  • RIGL $7.15
  • EFT $7.62
  • Revenue Growth
  • RIGL 105.62
  • EFT N/A
  • 52 Week Low
  • RIGL $12.66
  • EFT $11.10
  • 52 Week High
  • RIGL $43.72
  • EFT $13.44
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • EFT 43.69
  • Support Level
  • RIGL $39.00
  • EFT $12.00
  • Resistance Level
  • RIGL $42.08
  • EFT $12.24
  • Average True Range (ATR)
  • RIGL 2.32
  • EFT 0.08
  • MACD
  • RIGL -0.37
  • EFT 0.01
  • Stochastic Oscillator
  • RIGL 53.26
  • EFT 63.16

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest

Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.

Share on Social Networks: